TD-0903 for ALI Associated With COVID-19
Public ClinicalTrials.gov record NCT04402866. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multi-center Study of an Inhaled Pan-Janus Kinase Inhibitor, TD-0903, to Treat Symptomatic Acute Lung Injury Associated With COVID-19
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase 2 study will evaluate the efficacy, safety, pharmacodynamics and pharmacokinetics of inhaled TD-0903 compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with confirmed COVID-19 associated acute lung injury and impaired oxygenation.
Study identification
- NCT ID
- NCT04402866
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 235 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 24, 2020 (Actual)
- Primary completion
- Apr 21, 2021 (Actual)
- Completion
- Apr 21, 2021 (Actual)
- Last update posted
- Mar 17, 2022
2020 – 2021
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Theravance Biopharma Investigational Site | Duarte | California | 91010 | — |
| Theravance Biopharma Investigational Site | Denver | Colorado | 80220 | — |
| Theravance Biopharma Investigational Site | Sebring | Florida | 33870 | — |
| Theravance Biopharma Investigational Site | Boston | Massachusetts | 02135 | — |
| Theravance Biopharma Investigational Site | Fall River | Massachusetts | 02720 | — |
| Theravance Biopharma Investigational Site | Kalispell | Montana | 59901 | — |
| Theravance Biopharma Investigational Site | Glens Falls | New York | 12801 | — |
| Theravance Biopharma | Hyde Park | New York | 11040 | — |
| Theravance Biopharma Investigational Site | Columbus | Ohio | 43214 | — |
| Theravance Biopharma Investigational Site | Allentown | Pennsylvania | 18103 | — |
| Theravance Biopharma Investigational Site | Bethlehem | Pennsylvania | 18015 | — |
| Theravance Biopharma Investigational Site | Wenatchee | Washington | 98801 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04402866, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 17, 2022 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04402866 live on ClinicalTrials.gov.